Published: 19. April, 2022
Cessatech A/S today releases its results for the period 1 January – 31 March…
Cessatech A/S today releases its results for the period 1 January – 31 March 2022. The company is progressing with planned activities: Recruitment of trial 0206 is nearly complete (a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures) and we are currently finalising the preparation for the initiation of our pivotal trial with CT001 (0205). We anticipate trial 0205 to start recruitment during Q2 2022.
220419_Cessatech_Q1-2022_Report
“During the first quarter of 2022 we have nearly finalised the recruitment in our Phase 2 (0206) pharmacokinetic study with CT001, and importantly we announced Topline results of clinical trial 0204 investigating the absolute bioavailability of CT001 showed clinical relevant exposures following nasal administration. We are still pending formal approval of trial 0205 from regulatory authorities and we expect to start this study during Q2. We have been off to a good start of 2022 and anticipate a very exciting year for the Company.“ says Jes Trygved, CEO
